OrthologAL: A Shiny application for quality-aware humanization of non-human pre-clinical high-dimensional gene expression data.

Single-cell and spatial transcriptomics provide unprecedented insight into the inner workings of disease. Pharmacotranscriptomic approaches are powerful tools that leverage gene expression data for drug repurposing and treatment discovery in many diseases. Multiple databases attempt to connect human cellular transcriptional responses to small molecules for use in transcriptome-based drug discovery efforts.

MAT2a and AHCY inhibition disrupts antioxidant metabolism and reduces glioblastoma cell survival.

Glioblastoma (GBM) is a highly aggressive primary malignant adult brain tumor that inevitably recurs with a fatal prognosis. This is due in part to metabolic reprogramming that allows tumors to evade treatment. We therefore must uncover the pathways mediating these adaptations to develop novel and effective treatments.

Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations.

Purpose Of Review: At present, breast cancer represents the most common malignancy diagnosed in women worldwide. Due to the trend toward delayed childbearing, many women of reproductive age are being diagnosed with breast cancer and treated with chemotherapy or hormone therapy which can adversely affect their fertility. This literature review discusses the effects of breast cancer treatment on fertility and options for fertility preservation.

Impact of printing layer thickness on the flexural strength of nanocomposite 3D printed resins: An in vitro comparative study.

Background: This study evaluated the influence of various printing layer thicknesses with silicon dioxide nanoparticles (SiONPs) incorporated as a reinforcement material on the flexural strength of 3D-printed denture base resins.

Material And Methods: Asiga (DentaBASE, Asiga, Erfurt, Germany) and NextDent (Denture 3D+, NextDent B.V.

Glutaminase 2 as a therapeutic target in glioblastoma.

Glioblastoma (GBM) is the most common malignant primary adult brain tumor. Despite standard-of-care treatment, which consists of surgical resection, temozolomide (TMZ) treatment, and radiotherapy, the prognosis for GBM patients remains poor with a five-year survival rate of 5 %. With treatment, the median survival time is 14 months, suggesting the dire need for new, more effective therapies.